There has been a surge in the multidrug-resistant extraintestinal pathogenic Escherichia Coli (ExPEC).

Hence, to develop a commercial vaccine for extraintestinal pathogenic Escherichia coli (ExPEC), Sanofi partnered with Janssen and invested $175 million upfront.

The surge in multidrug-resistant ExPEC strains has led to higher mortality rates, reflecting the challenges in treatment.

Rising cases of invasive E. coli disease threaten older adults;

Also, multidrug-resistant strains exacerbate mortality, underscoring treatment challenges.

Recognizing this pressing issue, Sanofi's partnership with Janssen aims to deliver superior healthcare solutions, including a commercial vaccine for extraintestinal pathogenic Escherichia coli (ExPEC).

This collaboration will address the rising impact of ExPEC-related sepsis and mortality.

And it also aligns with efforts: